ADRB2 Gly16Arg polymorphism, asthma control and lung function decline

C. Rebordosa, M. Kogevinas, S. Guerra, F. Castro-Giner, D. Jarvis, L. Cazzoletti, I. Pin, V. Siroux, M. Wjst, J. M. Antò, R. De Marco, Xavier P. Estivill, A. G. Corsico, R. Nielsen, C. Janson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Arg/Arg homozygotes for the Gly16Arg polymorphism in the β 2-adrenoreceptor gene (ADRB2) have a reduced response to short-acting β 2-agonists but no effect has been associated with long-acting β 2-agonists (LABAs). We selected 604 subjects with current asthma from the European Community Respiratory Health Study to evaluate whether asthma control and lung function decline were associated with Gly16Arg polymorphism, and to test whether LABA or inhaled corticosteroid (ICS) use modified these effects. There was an increased risk of noncontrolled asthma (OR 1.33, 95% CI 1.01-1.75; p=0.046) for each Arg allele. Among nonusers of ICS, the odds ratio of noncontrolled asthma among Arg/Arg versus Gly/Gly subjects was 2.73 (95% CI 1.28-5.82; p=0.009). No increased risk of noncontrolled asthma associated with the Arg allele was observed among ICS and/or LABA users. For each Arg allele, a mean±SE decrease in decline in forced expiratory volume in 1 s of 7.7±2.5 mL·yr -1 was found (p-value for trend 0.003), irrespective of ICS or LABA use. Arg/Arg subjects had an increased risk of bronchial hyperresponsiveness (BHR) versus Gly/Gly subjects, with an odds ratio of 2.51 (95% CI 1.12-5.63; p=0.025) if they did not use ICS. The Arg allele was associated with poorer asthma control, a steeper lung function decline and BHR. Absence of genotypic effects on asthma control among ICS users may be due to reversed β 2-adrenoreceptor desensitisation.

Original languageEnglish
Pages (from-to)1029-1035
Number of pages7
JournalEuropean Respiratory Journal
Volume38
Issue number5
DOIs
Publication statusPublished - 1 Nov 2011
Externally publishedYes

Fingerprint

Asthma
Adrenal Cortex Hormones
Lung
Alleles
Odds Ratio
Forced Expiratory Volume
Homozygote
European Union
Health
Genes

Keywords

  • β -adrenoreceptor polymorphisms
  • Asthma control
  • Bronchial hyperresponsiveness
  • Corticosteroids
  • Lung function

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Rebordosa, C., Kogevinas, M., Guerra, S., Castro-Giner, F., Jarvis, D., Cazzoletti, L., ... Janson, C. (2011). ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. European Respiratory Journal, 38(5), 1029-1035. https://doi.org/10.1183/09031936.00146310

ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. / Rebordosa, C.; Kogevinas, M.; Guerra, S.; Castro-Giner, F.; Jarvis, D.; Cazzoletti, L.; Pin, I.; Siroux, V.; Wjst, M.; Antò, J. M.; De Marco, R.; Estivill, Xavier P.; Corsico, A. G.; Nielsen, R.; Janson, C.

In: European Respiratory Journal, Vol. 38, No. 5, 01.11.2011, p. 1029-1035.

Research output: Contribution to journalArticle

Rebordosa, C, Kogevinas, M, Guerra, S, Castro-Giner, F, Jarvis, D, Cazzoletti, L, Pin, I, Siroux, V, Wjst, M, Antò, JM, De Marco, R, Estivill, XP, Corsico, AG, Nielsen, R & Janson, C 2011, 'ADRB2 Gly16Arg polymorphism, asthma control and lung function decline', European Respiratory Journal, vol. 38, no. 5, pp. 1029-1035. https://doi.org/10.1183/09031936.00146310
Rebordosa C, Kogevinas M, Guerra S, Castro-Giner F, Jarvis D, Cazzoletti L et al. ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. European Respiratory Journal. 2011 Nov 1;38(5):1029-1035. https://doi.org/10.1183/09031936.00146310
Rebordosa, C. ; Kogevinas, M. ; Guerra, S. ; Castro-Giner, F. ; Jarvis, D. ; Cazzoletti, L. ; Pin, I. ; Siroux, V. ; Wjst, M. ; Antò, J. M. ; De Marco, R. ; Estivill, Xavier P. ; Corsico, A. G. ; Nielsen, R. ; Janson, C. / ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. In: European Respiratory Journal. 2011 ; Vol. 38, No. 5. pp. 1029-1035.
@article{460febd4054f4964ae0194b7cf87ea7f,
title = "ADRB2 Gly16Arg polymorphism, asthma control and lung function decline",
abstract = "Arg/Arg homozygotes for the Gly16Arg polymorphism in the β 2-adrenoreceptor gene (ADRB2) have a reduced response to short-acting β 2-agonists but no effect has been associated with long-acting β 2-agonists (LABAs). We selected 604 subjects with current asthma from the European Community Respiratory Health Study to evaluate whether asthma control and lung function decline were associated with Gly16Arg polymorphism, and to test whether LABA or inhaled corticosteroid (ICS) use modified these effects. There was an increased risk of noncontrolled asthma (OR 1.33, 95{\%} CI 1.01-1.75; p=0.046) for each Arg allele. Among nonusers of ICS, the odds ratio of noncontrolled asthma among Arg/Arg versus Gly/Gly subjects was 2.73 (95{\%} CI 1.28-5.82; p=0.009). No increased risk of noncontrolled asthma associated with the Arg allele was observed among ICS and/or LABA users. For each Arg allele, a mean±SE decrease in decline in forced expiratory volume in 1 s of 7.7±2.5 mL·yr -1 was found (p-value for trend 0.003), irrespective of ICS or LABA use. Arg/Arg subjects had an increased risk of bronchial hyperresponsiveness (BHR) versus Gly/Gly subjects, with an odds ratio of 2.51 (95{\%} CI 1.12-5.63; p=0.025) if they did not use ICS. The Arg allele was associated with poorer asthma control, a steeper lung function decline and BHR. Absence of genotypic effects on asthma control among ICS users may be due to reversed β 2-adrenoreceptor desensitisation.",
keywords = "β -adrenoreceptor polymorphisms, Asthma control, Bronchial hyperresponsiveness, Corticosteroids, Lung function",
author = "C. Rebordosa and M. Kogevinas and S. Guerra and F. Castro-Giner and D. Jarvis and L. Cazzoletti and I. Pin and V. Siroux and M. Wjst and Ant{\`o}, {J. M.} and {De Marco}, R. and Estivill, {Xavier P.} and Corsico, {A. G.} and R. Nielsen and C. Janson",
year = "2011",
month = "11",
day = "1",
doi = "10.1183/09031936.00146310",
language = "English",
volume = "38",
pages = "1029--1035",
journal = "Acta tuberculosea Scandinavica",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "5",

}

TY - JOUR

T1 - ADRB2 Gly16Arg polymorphism, asthma control and lung function decline

AU - Rebordosa, C.

AU - Kogevinas, M.

AU - Guerra, S.

AU - Castro-Giner, F.

AU - Jarvis, D.

AU - Cazzoletti, L.

AU - Pin, I.

AU - Siroux, V.

AU - Wjst, M.

AU - Antò, J. M.

AU - De Marco, R.

AU - Estivill, Xavier P.

AU - Corsico, A. G.

AU - Nielsen, R.

AU - Janson, C.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Arg/Arg homozygotes for the Gly16Arg polymorphism in the β 2-adrenoreceptor gene (ADRB2) have a reduced response to short-acting β 2-agonists but no effect has been associated with long-acting β 2-agonists (LABAs). We selected 604 subjects with current asthma from the European Community Respiratory Health Study to evaluate whether asthma control and lung function decline were associated with Gly16Arg polymorphism, and to test whether LABA or inhaled corticosteroid (ICS) use modified these effects. There was an increased risk of noncontrolled asthma (OR 1.33, 95% CI 1.01-1.75; p=0.046) for each Arg allele. Among nonusers of ICS, the odds ratio of noncontrolled asthma among Arg/Arg versus Gly/Gly subjects was 2.73 (95% CI 1.28-5.82; p=0.009). No increased risk of noncontrolled asthma associated with the Arg allele was observed among ICS and/or LABA users. For each Arg allele, a mean±SE decrease in decline in forced expiratory volume in 1 s of 7.7±2.5 mL·yr -1 was found (p-value for trend 0.003), irrespective of ICS or LABA use. Arg/Arg subjects had an increased risk of bronchial hyperresponsiveness (BHR) versus Gly/Gly subjects, with an odds ratio of 2.51 (95% CI 1.12-5.63; p=0.025) if they did not use ICS. The Arg allele was associated with poorer asthma control, a steeper lung function decline and BHR. Absence of genotypic effects on asthma control among ICS users may be due to reversed β 2-adrenoreceptor desensitisation.

AB - Arg/Arg homozygotes for the Gly16Arg polymorphism in the β 2-adrenoreceptor gene (ADRB2) have a reduced response to short-acting β 2-agonists but no effect has been associated with long-acting β 2-agonists (LABAs). We selected 604 subjects with current asthma from the European Community Respiratory Health Study to evaluate whether asthma control and lung function decline were associated with Gly16Arg polymorphism, and to test whether LABA or inhaled corticosteroid (ICS) use modified these effects. There was an increased risk of noncontrolled asthma (OR 1.33, 95% CI 1.01-1.75; p=0.046) for each Arg allele. Among nonusers of ICS, the odds ratio of noncontrolled asthma among Arg/Arg versus Gly/Gly subjects was 2.73 (95% CI 1.28-5.82; p=0.009). No increased risk of noncontrolled asthma associated with the Arg allele was observed among ICS and/or LABA users. For each Arg allele, a mean±SE decrease in decline in forced expiratory volume in 1 s of 7.7±2.5 mL·yr -1 was found (p-value for trend 0.003), irrespective of ICS or LABA use. Arg/Arg subjects had an increased risk of bronchial hyperresponsiveness (BHR) versus Gly/Gly subjects, with an odds ratio of 2.51 (95% CI 1.12-5.63; p=0.025) if they did not use ICS. The Arg allele was associated with poorer asthma control, a steeper lung function decline and BHR. Absence of genotypic effects on asthma control among ICS users may be due to reversed β 2-adrenoreceptor desensitisation.

KW - β -adrenoreceptor polymorphisms

KW - Asthma control

KW - Bronchial hyperresponsiveness

KW - Corticosteroids

KW - Lung function

UR - http://www.scopus.com/inward/record.url?scp=80355148633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80355148633&partnerID=8YFLogxK

U2 - 10.1183/09031936.00146310

DO - 10.1183/09031936.00146310

M3 - Article

C2 - 21436355

AN - SCOPUS:80355148633

VL - 38

SP - 1029

EP - 1035

JO - Acta tuberculosea Scandinavica

JF - Acta tuberculosea Scandinavica

SN - 0903-1936

IS - 5

ER -